CEL-SCI Corp CVM:NYSE American

RT Quote | NYSE American | USD
Last | 02/25/21 EST
18.36UNCH (UNCH)
Volume
1,048,601
52 week range
6.35 - 40.91

...

Loading . . .

KEY STATS

  • Open19.34
  • Day High21.23
  • Day Low18.36
  • Prev Close18.36
  • 52 Week High40.91
  • 52 Week High Date01/27/21
  • 52 Week Low6.35
  • 52 Week Low Date02/26/20
  • Market Cap744.13M
  • Shares Out40.53M
  • 10 Day Average Volume0.79M
  • Dividend-
  • Dividend Yield-
  • Beta1.92
  • 1 Year % Change12.29

RATIOS/PROFITABILITY

  • EPS (TTM)-0.88
  • P/E (TTM)-20.85
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-28.652M
  • ROE (MRQ)-174.32%
  • Revenue (MRQ)520,000.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-6,275.20%
  • Debt To Equity (MRQ)39.87%

EVENTS

  • Earnings Date05/13/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest CEL-SCI Corp News

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for...
Geert Kersten Esq.
Chief Executive Officer
Address
8229 Boone Blvd Ste 802
Vienna, VA
22182-2634
United States